A large-cap global pharmaceutical company with an immunology portfolio used Captario SUM® to understand what assets to prioritize within...

A large-cap global pharma company with a robust, diversified portfolio used Captario SUM® to model portfolio launch behavior over time...

Since its founding in 2012, Captario has never been the traditional company where ”you go to the office.” While there is a physical...

One method of illustrating risk is to show the value at risk (VaR). Plotting the fifth percentile from the simulated outputs in the left...

What challenges do pharmaceutical companies make regarding portfolio decisions? The portfolio elements are high-risk, expensive, take a...

At Captario, we continuously explore risk and return metrics for R&D portfolio assets, and we strive to stay on top of the many excellent...

Drug development is a risky business. Development products carry technical and regulatory risks (PTRS), operational risks (delays and...

Overall, everything in an organization, and especially a profit driven organization, is possible to quantify. If you have a tough...

This is a short story of when I was away from home in a city I had never been to before. I had been away all day, and all that was left...

Understanding what decisions to make about the future is no easy task. In an earlier article, we outlined the 6 best practices in pharma...

Artificial Intelligence, or AI as most everyone calls it, is an exciting term with very little agreement on what it actually means....

To many people, holistic modeling may seem a novel practice. Actually, holistic modeling is rather old, seen in 1772 in a letter by...

Understanding the forecasting process and making decisions based on those predictions is not done easily. Without time-machines or real...

“A great practice in portfolio decision quality strategically manages uncertainty and offers decision makers more reliable foundations to...

Recently, Captario had the opportunity to present to a non-profit organization that uses medicine development as one of its...

Case Study Background Launching a new molecular entity (NME) has always been an uncertain endeavor for the pharmaceutical industry. To...

Industries are continuously evolving, and the pharma industry is no exception. There are trends impacting the way we think about pharma,...

Is there any value in uncertainty? Do you know uncertainty? Is uncertainty a friend, or a foe? Let's start by asking another question:...

A drug development team saw three paths to get to a successful launch: 1. Best Case: Test the response rate in a small cohort of 20...

A while ago I was engaged in a client project where we developed the launch strategy for a compound targeted for multiple indications....